Avalo Therapeutics (AVTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Avalo Therapeutics (AVTX) is Moderate Underperform.

The composite score behind that read is -0.33, weighing +0.00 of bullish evidence against -0.33 bearish.

Avalo Therapeutics last closed at $14.60, -2.60% on the session.

Against the IVW growth benchmark the position is -3.52% over the forecast window.

The read is built from 12 underlying insights — 0 bullish and 12 bearish.

Agreement across those insights is 100%.

14 graded predictions for AVTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Avalo Therapeutics in the 16th percentile on return on equity, where 100 is best.

Avalo Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $803.91M.

StockMap tracks Avalo Therapeutics as the 135th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Avalo Therapeutics ranks 264th of 344 in the group, against a group median of -0.21.